Funding
INTEGRATE II is supported by an untied educational grant from Bayer HealthCare Pharmaceuticals to the Australasian Gastro-Intestinal Trials Group to conduct the study independently. Bayer HealthCare Pharmaceuticals are also providing the study drug regorafenib. Bristol Myers Squibb are providing the study drug nivolumab.